GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.

Journal of Clinical Oncology 2026

View at publisher
Authors: Zunairah Shah, Jasmin Hundal, Safa Saadat Afridi, Sumbal Aziz, Trie Arni Djunadi, Vaishali Deenadayalan, Song Yao, Sheheryar Kairas Kabraji, Neil M. Iyengar, Shipra Gandhi
DOI: 10.1200/jco.2026.44.16_suppl.10548
Cited by: 1

Abstract

10548 Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for weight management and cardiometabolic risk (CMR) reduction, yet their association with breast cancer (BC) incidence and survival in non-diabetic women with elevated BMI remains unclear. We evaluated the relationship between GLP-1 RA exposure and incident BC, as well as overall survival (OS), in a large real-world (RW) cohort of women without laboratory-defined diabetes. Methods: We conducted a retrospective cohort study using the TriNetX US Collaborative Network including female patients (pts) with BMI 25–35 kg/m². Age

Fields of Study & Subjects

Metabolism Diabetes and Cancer Cancer Risks and Factors Advanced Breast Cancer Therapies

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
16_suppl
Pages
10548–10548
Publication date
27 May 2026
Language
EN